Access to >100 Million Lives in Europe

Prior to August 2017, there were only a few data sources that were easily accessible in Europe. All of these databases are relatively small (approx. 5-7 million) and primary care-based.

Since August 2017, the French agency has made the French National Health Data System—SNDS data—accessible to private organisations (pharmaceutical companies need to access the data via a certified third-party). The access request is required to demonstrate a scientific or medical research need rather than through academic affiliations or requests from agencies.

Certara Evidence & Access is proud to be the first successful non-academic applicant to receive a positive response towards the French SNDS data for access to 65 million lives. Combined with our own ANSER Real World Data Sets and other databases in Europe, this offers a combined population of more than 100 million lives in Europe.

With in-depth knowledge of the French context, having more than 15 years of experience in conducting observational studies in France, Certara Evidence and Access is your best choice for accessing SNDS data.

“Since 2017, […] the collaboration with Certara’s dynamic team has always been constructive and positive, resulting in the signature of a multitude of contracts governing the provision of SNDS data for the realization of various studies in the field of health.” – Julius Kemme, French Health Insurance (CNAM, SNDS data owner)

SNDS Data Characteristics

SNDS data can be extremely powerful as the database size is very large (65 million lives) and representative of the French population, even for rare diseases. The SNDS can provide sample sizes of >1,000. Data for 10 years longitudinal follow up for >85% of the French population is available and anonymized on:

  • Socio-demographics
  • Medical characteristics
  • Ambulatory care
  • Hospitalizations
  • Diagnosis
  • Drugs and procedures
  • Mortality data
  • Costs data

Unlike US databases, all healthcare use of the patient can be tracked since birth/first residence in France for 10 years and there is no loss to follow up except for emigration.

Download Brochure
SNDS Data + Analysis + Expert Study Design

Whether your drug is still in development or on the market, evidence is needed. From niche needs identification, justifying access, differentiating value, quantifying an opportunity, to demonstrating benefit/risk, Certara offers real world data solutions for every need.

Certara’s team of epidemiologists, statisticians and real world data specialists provides analysis and study design services that leverage SNDS data and other healthcare databases for various international markets to help assess:

  • Impact of medicines and health technologies on drug and resource utilization
  • Natural History, Health and Economic Burden of Disease
  • Comparative/relative effectiveness of medicines and health technologies
Start a Conversation
Access to 100 million population datasets

Combined with our own ANSER Real World Data Sets for pain, cardiology, neurology, and oncology, and other databases in Europe, these reliable, high quality datasets offer a combined population of more than 100 million lives in Europe.

Experience with other specialized European datasets include:

  • CPRD (UK) (5-7 million lives)
  • German Sickness Fund (5-7 million lives)
  • Nordics Database (15 million lives)
  • Hungary (9 million lives)

As key opinion leaders, Certara’s real world data specialists speak regularly at international industry events, including ISPOR.

Contact Us
Our Team
Sumeet Bakshi VP, Real World Data Solutions

Sumeet is VP, Real World Evidences Solutions, in Certara’s Evidence, Value & Access group. Sumeet qualified as a physician from the University of Mumbai (India) and holds an MBA from the Saïd Business School, University of Oxford (UK). Prior to joining Analytica Laser, he had gained multi-disciplinary experience working through roles in sales, brand management, and strategic planning in companies such as Pfizer and J&J.

Sumeet joined Analytica Laser (now part of Certara) in 2010 and has developed extensive expertise in real-world evidence strategies and access globally. At ANALYTICA LASER, he has set up real world research platforms for complex study programs in many therapy areas and has also consulted for clients on projects in the areas of real-world research, evidence generation strategy, strategic positioning and pricing & reimbursement strategy, amongst others.

Sumeet brings strategic thinking, insightful perspectives and strong project/program management skills to the projects that he contributes to. He is a senior member of Certara’s Evidence, Value and Access group and provides leadership to the Real World Data Solutions practice within Certara EVA.

Nadia Quignot Director, Decision Analytics & Real World Evidence

Nadia Quignot is Director, Real World Data solutions & Data analytics at Certara. Over the last >12 years, Nadia has worked on the development of methods to inform risk and benefit/risk assessment and has coordinated a range of (real world) data analytics projects, for European bodies and pharma companies. As a safety scientist at Roche Pharma, she was in charge of risk and benefit/risk evaluations for anti-inflammatory and anti-cancer drugs. In the R&D projects she conducted for European bodies, she was particularly involved in hazard characterization of drugs, pesticides and other food-related and environmental contaminants.

Nadia joined Analytica Laser in 2013 and has developed an extensive expertise in real-world evidence strategies and model-based analytics. She has been coordinating modelling initiatives and a range of (real world) data analytics projects, for European bodies and pharma companies, including directing >15 French SNDS database projects.

Nadia holds a PhD in Pharmaco/toxicometrics from Paris 5 René Descartes University.

Back to top